Cambrex Zenara Facility Gains EU GMP Approval

Cambrex Corp. has received GMP compliance certification from the Danish Medicines Agency (DKMA) for its manufacturing site in Hyderabad, India, following an audit conducted in October 2010. The DKMA Certificate is accepted by all EU Health Authorities and by authorities of several other countries.

The DKMA certification allows the company to expedite the launch of Nicotine Replacement Therapy (NRT) products in Europe, in addition to offering finished dosage forms of other pharmaceutical products to European customers through an integrated value chain.

Ashok Narasimhan, president of Cambrex Zenara, said, “We are very pleased with the results of the DKMA inspection. This commercially important and significant milestone for Cambrex confirms our commitment to quality in every aspect of operations management and reflects our efforts to sustain and continuously improve quality platforms.”